5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model

详细信息    查看全文

• 作者：Elisabetta Tronci ; Carlo Lisci ; Roberto Stancampiano ; Camino Fidalgo ; Maria Collu ; Paola Devoto ; Manolo Carta
• 关键词：5-HTP ; 5-hydroxy-tryptophan ; 6-OHDA ; 6-hydroxy-dopamine ; AIMs ; abnormal involuntary movements ; DA ; dopamine ; LID ; l-DOPA-induced dyskinesia ; PD ; Parkinson's disease ; SSRIs ; serotonin reuptake inhibitors ; TH ; tyrosine hydroxylase
• 刊名：Neurobiology of Disease
• 出版年：2013
• 出版时间：December, 2013
• 年：2013
• 卷：60
• 期：Complete
• 页码：108-114
• 全文大小：698 K

文摘

The serotonin system has recently emerged as an important player in the appearance of l-DOPA-induced dyskinesia (LID) in experimental models of Parkinson's disease, as it provides an unregulated source of l-DOPA-derived dopamine release in the dopamine-depleted striatum. Accordingly, toxin lesion or pharmacological silencing of serotonin neurons suppressed LID in the rat and monkey models of Parkinson's disease. However, 5-HT1 receptor agonists were also found to partially reduce the therapeutic effect of l-DOPA.

In this study, we evaluated whether enhancement of the serotonin tone induced by the administration of the serotonin precursor 5-hydroxy-tryptophan (5-HTP) could affect induction and expression of LID, as well as the therapeutic effect of l-DOPA, in 6-OHDA-lesioned rats.

Drug na?ve and l-DOPA-primed 6-OHDA-lesioned rats were chronically treated with a daily injection of l-DOPA (6 mg/kg plus benserazide, s.c.) alone, or in combination with 5-HTP (24-48 mg/kg, i.p.). The abnormal involuntary movements (AIMs) test, as well as the stepping and the motor activity tests, were performed during the chronic treatments.

Results showed that 5-HTP reduced the appearance of LID of about 50 % at both tested doses. A partial reduction of the therapeutic effect of l-DOPA was seen with the higher but not with the lower dose of 5-HTP. 5-HTP 24 mg/kg was also able to reduce the expression of dyskinesia in l-DOPA-primed dyskinetic rats, to a similar extent than in l-DOPA-primed rats.

Importantly, the antidyskinetic effect of 5-HTP 24 mg/kg does not appear to be due to a competition with l-DOPA for crossing the blood-brain barrier; in fact, similar l-DOPA striatal levels were found in l-DOPA only and l-DOPA plus 5-HTP 24 mg/kg treated animals. These data further confirm the involvement of the serotonin system in the appearance of LID, and suggest that 5-HTP may be useful to counteract the appearance of dyskinesia in Parkinson's disease patients.